drugset
Drugs / Infanrix-IPV/Hib
last change Aug 2018 re-read 3 minutes ago

Infanrix-IPV/Hib

also known as DTPa-IPV/Hib · SB213503

Vaccine

Developed for
diphtheria · haemophilus infectious disease · poliomyelitis · tetanus
Investigated by
GlaxoSmithKline

Trials 1

today NCT03128489 · Ph 3
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03128489 Dec 2017 → Aug 2018 diphtheria, haemophilus infectious disease, poliomyelitis, tetanus GlaxoSmithKline Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Infanrix-IPV/Hib “DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503)” NCT03128489 ↗
1

NCT03128489 ↗
Known as DTPa-IPV/Hib “DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503)” NCT03128489 ↗
Known as SB213503 “DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503)” NCT03128489 ↗
Modality Vaccine “DTPa-IPV/Hib Conjugate Vaccine” NCT03128489 ↗
Route Intramuscular “The vaccine will be administered intramuscularly” NCT03128489 ↗